DOCSLIB.ORG

Investor Relations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investor Relations Investor Relations June 2020 Contents . Lonza at a Glance . Full-Year 2019 Overview . Outlook 2020 . Lonza Segments . Pharma Biotech & Nutrition (LPBN) . Specialty Ingredients (LSI) . Appendices Note: Since 1 March 2019, Lonza has been operating in a Lonza Pharma Biotech & Nutrition segment and a Lonza Specialty Ingredients segment. Restated 2018 financials are published here. 2 2 2 Lonza at a Glance Lonza – Leading CDMO Player Globally, and Leading in Microbial Control Substantial scale and strong growth across all key metrics 70% of Group 6.8% 4.2bn 980 bps sales Sales CAGR 2019 LPBN Sales CORE EBITDA Margin 32.9% 2012-2019 in CHF Improvement 2012-2019 2019 LPBN CORE EBITDA Margin Pharma Biotech & Nutrition 5.9bn (LPBN) 2019 Sales in CHF 1.7bn 2019 LSI Sales In CHF 27.4% 2019 CORE EBITDA 17.8% Margin 2019 LSI >575 CORE EBITDA Margin 30% of Active Patent Families >800 Group Brands Specialty sales >55 15,468 Ingredients Employees End of 2019 Manufacturing Sites (LSI) 123 years of history *Growth rates based on reported figures at actual exchange rates. No adjustment for acquisitions and divestments reflected, except 2018 and 2019 figures, which are restated for reorganization of Lonza's Segments LPBN / LSI (excluding Water Care business as discontinued operations) CORE definition: See appendix 4 Current Business Portfolio Nutritional hard capsules business becoming part of LPBN Organizational changes in 2019 Lonza Pharma Biotech & Nutrition (LPBN) Lonza Specialty Ingredients (LSI) Alignment of the scope of segments CDMO Services Businesses Microbial-Control Solutions . Integrating the nutritional hard capsule business Small molecules Professional hygiene and small portfolio for nutritional ingredients Mammalian and microbial Home and personal care into Pharma & Biotech Cell and gene technologies Wood protection Material protection . Designed to strengthen collaboration and Product Businesses Paints & coatings leverage synergies within the capsules businesses Bioscience Crop protection Capsule systems Specialty Chemicals Services Nutritional ingredients Start of carve-out of Lonza Specialty Ingredients Composites Custom development & manufacturing Performance chemicals & intermediates . LSI will operate independently, but remain a fully owned segment of Lonza Group . Increase focus on LSI priorities and optimal CHF 4.2bn 11,148 CHF 1.7bn 2,504 organization model Sales Employees Sales Employees 5 Lonza Geographic Overview Capitalizing on our global footprint (overview manufacturing and R&D sites, and sales offices) Lonza has more than 100 sites and offices 2019 sales by region 1 Asia Other 14.2% 1.7% Europe 38% Americas 46.1% Pharma Biotech & Nutrition Specialty Ingredients 1 Includes Africa, Australia & New Zealand and Others 6 Progressing LSI Carve-out According to Timelines and Defined Milestones Completion of operational separation expected mid-2020 Cross-functional workstreams Selected milestones in 2020: . Dedicated legal entities by business/segment (operational in Carve-out H1 2020) Tax structure Visp Nansha . Assignment of employees to segments Regional Global real Carve-out HR carve-out estate financials . Set up of service and supply agreements between the two segments progressing Environment IT Comms Treasury . Continued progress in setting up systems to reflect new legal entity structure Procurement Logistics Legal / IP Regulatory 7 Full-Year 2019 Overview Full-Year 2019 Corporate Overview Pharma Biotech & Nutrition driving performance, headwinds in Specialty Ingredients . Lonza Group delivers on guidance1 with 6.8% sales growth, resulting in CHF 5.9bn, and CHF 1.6bn CORE EBITDA, resulting in a 27.4% margin . Pharma Biotech & Nutrition (LPBN) as driver, with 11.0% sales growth and 32.9% CORE EBITDA margin . Specialty Ingredients (LSI) shows improved 17.8% CORE EBITDA margin, despite sales growth of -3.2%; carve-out progressing according to plan . Lonza Group outlook 2020: above mid single-digit sales growth2, driven by high single-digit sales growth in LPBN, and overall stable CORE EBITDA margin . Mid-Term Guidance 2022 confirmed, supported by solid building blocks 1 Guidance for FY 2019: mid to high single-digit sales growth and sustained high CORE EBITDA margin level 2 Outlook 2020 in constant currency CORE definition: See appendix 9 Full-Year 2019 Results Comparison vs. Prior Year (Continuing Operations) 5,920million 1,620million1 27.4%1 Sales (CHF) +6.4%6.8% CORE EBITDA (CHF) 7.2% CORE EBITDA Margin +3010 bpsbps 13.59CHF2 9.1% 15,468 CORE EPS Diluted 10.113.4% % ROIC 110110bps bps Employees 1107.2 bps% 1 IFRS 16 accounting adjustment on leases had a positive CORE EBITDA impact of CHF 33 million in 2019 (60 bps positive CORE EBITDA margin impact), offset by costs related to the divestment of the Water Care business and carve out of Specialty Ingredients (50 bps negative CORE EBITDA margin impact). IFRS Results – Continuing Business: EBITDA – CHF 1,525 million; 6.7 % change, EBITDA Margin – 25.8%; 0bps change 2 EPS diluted – CHF 10.22; 16.5% change (IFRS Results – Continuing Business) CORE definition: See appendix 10 Segment Financial Performance Full-Year 2019 Comparison vs. Prior Year (Continuing Operations) Pharma Biotech & Nutrition 4,167million 1,371million1 32.9%2 Sales (CHF) 10.811.0% % CORE EBITDA (CHF) 9.710.0% % CORE EBITDA Margin -30(30bps) bps Specialty Ingredients 1,693million 302million3 17.8%4 Sales (CHF) -3.8(3.2%) % CORE EBITDA (CHF) +9.7(0.3%) % CORE EBITDA Margin + 2050bps bps 1 CORE EBITDA excl. IFRS 16 – CHF 1,347 million; 8.1% change 2 CORE EBITDA Margin excl. IFRS 16 – 32.3%; (90bps) change 3 CORE EBITDA excl. IFRS 16 – CHF 297 million; (2%) change 4 CORE EBITDA Margin excl. IFRS 16 – 17.5%; 20bps change CORE definition: See appendix 11 Lonza Net Leverage 2017 to 2019 Continued deleveraging on the back of strategic growth investments Net Leverage (Net Debt / CORE EBITDA) Solid investment grade . Deleveraging well below guidance of less est. 2.8x than 2x net debt/CORE EBITDA by end 2019 2.7x 2.3x . Debt reduction behind strong operational 2.1x 1.83x free cash flow and divestment of Water Care business with net proceeds of CHF 620 million . Successful refinancing of loan facilities in 2019, leveraging successful initiation of S&P BBB+ credit rating with stable outlook in 2019 . Commitment to maintain solid investment At closing of Capsugel FY20172 FY20183 HY20193 2019 grade rating going forward acquisition1 1 Net Debt/CORE EBITDA is calculated based on the CORE EBITDA of the last 12 months, including Capsugel. The Capsugel acquisition closed on 5 July 2017 2 2017 including Capsugel as of 5 July 2017, restated for IFRS 15 3 Net Debt/CORE EBITDA is calculated based on the CORE EBITDA of the last 12 months CORE definition: See appendix 12 Lonza Financial Performance Trends from 2012 to 2019 Sales in CHF million CORE EBITDA in CHF million CAGR 2012 – 2019 – 6.8% 27.4 27.3 1,511 Total Growth – 58.2% 5,920 % Margin 26.5 5,542 1,620 5,083 1,511 1,349 4,132 22.2 3,803 20.4 20.9 3,741 3,584 3,640 19.8 17.6 918 743 793 657 711 2012 2013 2014 2015 2016 2017 pro- 2018 2019 2012 2013 2014 2015 2016 2017 pro- 2018 2019 forma restated forma restated CORE RONOA in % CORE EPS Diluted in CHF CAGR 2012 – 2019 – 17.1% 13.6 31.4 12.0 30.0 Total Growth – 202.2% 28.5 10.8 21.5 8.4 16.4 6.8 6.8 14.3 12.3 11.0 4.5 5.0 2012 2013 2014 2015 2016 2017 2018 2019 2012 2013 2014 2015 2016 2017 2018 2019 *Growth rates based on reported figures at actual exchange rates. No adjustment for acquisitions and divestments reflected, except 2018 and 2019 figures, which are restated for reorganization of Lonza's Segments LPBN / LSI (excluding Water Care business as discontinued operations) CORE definition: See appendix 13 Outlook 2020 Outlook 2020 The year ahead for Lonza Group and its segments . High single-digit sales growth in Pharma Biotech & Nutrition and low single-digit sales growth in Specialty Ingredients anticipated in 2020 Above mid single-digit . Overall stable CORE EBITDA margin despite growth projects in sales growth LPBN with CAPEX investments expected to remain at 2019 levels, related OPEX and start-up cost for significant projects scheduled to start operations by the end of 2020 . Outlook factors in continued macroeconomic uncertainty and Stable CORE some potential ongoing headwinds in the cyclical parts of EBITDA Lonza's Specialty Ingredients businesses margin level Outlook 2020 is based on present business composition, the current macroeconomic environment, existing visibility and constant exchange rates. CORE definition: See appendix 15 Confirming Mid-Term Guidance 2022 Building blocks in place to deliver on Guidance Pharma Biotech & Nutrition Specialty Ingredients (LPBN) (LSI) Sales CHF CORE RONOA Sales Growth High single-digits Low to mid single-digits 7.1 billion 35% 2017PF1-2022 2022 CORE >30% >20% EBITDA Margin . Manufacturing excellence . Microbial control expertise CORE EBITDA Double-Digit . Operating leverage . Procurement and supply- Margin 30.5% ROIC Building . Growth projects and chain excellence Blocks CAPEX investments . Productivity gains 1 Pro forma as Lonza Full-Year 2017 financial results (restated for IFRS 15) include Capsugel Full-Year 2017 financial results Mid-Term Guidance 2022 is based on present business composition, the current macroeconomic environment, existing visibility and constant exchange rates. CORE definition: See appendix 16 Lonza Priorities 2020 Setting up the business for continued growth . Delivering financial targets 2020 and building blocks for Mid- Term Guidance 2022 . Realizing LSI carve-out on time and on budget . Focusing on execution of growth projects and new partnerships in LPBN, as well as strengthening R&D and innovation . Continuing talent attraction and retention as well as ensuring constant pipeline to develop the future leaders of the company . Establishing clearer targets and action plan for implementation of environmental, social and governance (ESG) measures .
Load more

Recommended publications
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Alcon-20-F-2020.Pdf
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report __________ Commission file number: 001-31269 Alcon Inc. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's name into English) Switzerland (Jurisdiction of incorporation or organization) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Royce Bedward, Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland; Tel: +41 58 911 20 00; Fax +41 58 911 32 22 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol(s) Name of each exchange on which registered SIX Swiss Exchange Ordinary Shares, nominal value CHF 0.04 per share ALC New York Stock Exchange Securities registered or to be registered pursuant to Section 12(g) of the Act. None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
    [Show full text]
  • Corporate Governance Report
    Corporate Governance Report 30 June 2009 Board of Directors Executive Board Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2 Professional background and other activities and functions 4 1.3 Cross-involvement 7 1.4 Internal organisational structure 8 2. Executive Board 10 2.1 Members of the Executive Board 10 2.2 Professional background and other activities and functions 11 General Organisation of Nestlé S.A. 15 Situation at 30 June 2009 © 2009, Nestlé S.A., Cham and Vevey (Switzerland) Concept Nestlé S.A., Group Governance Design Nestec Ltd., SGDU, Corporate Identity & Design 2 Nestlé Corporate Governance Report June 2009 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, Contact for Media: including a separate Compensation Report, which Nestlé S.A. forms an integral part of the annual Management Report. Corporate Media Relations We therewith comply with the requirements of the Avenue Nestlé 55 SIX Swiss Exchange (SIX) and its Corporate Governance CH - 1800 Vevey (Switzerland) Directive. tel. +41 (0)21 924 22 00 The present document is a partial update of the fax +41 (0)21 922 63 34 Nestlé Corporate Governance Report 2008, indicating e-mail: [email protected] changes occurred on the Board of Directors and the Executive Board up to 30 June 2009. Contact for Investors: The annual Management Report is available Nestlé S.A. on-line as a PDF file at http://www.nestle.com in English, Investor Relations French and German. Copies can be ordered at: Avenue Nestlé 55 http://www.nestle.com/Media_Center/Order.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 — Financial Overview Annual Report 2015 Financial Overview Corporate Governance Report Remuneration Report Report Financial Annual Report 2015 Financial Overview Financial Report Remuneration Report Corporate Governance Report Financial Report Remuneration Report Consolidated Financial Statements Compensation and Performance Overview 2015 100 Consolidated Balance Sheet 4 Compensation-Setting Process 101 Consolidated Income Statement 5 Compensation Components 103 Consolidated Statement of Comprehensive Income 5 Compensation of the Board of Directors 104 Consolidated Cash Flow Statement 6 Compensation of the Executive Committee 106 Consolidated Statement of Changes in Equity 7 Share Ownership of the Members of the Board of Notes to the Consolidated Financial Statements 8 Directors and the Executive Committee 116 Report of the Statutory Auditor 81 Report of the Statutory Auditor 119 Financial Statements of Lonza Group Ltd, Basel Balance Sheet 82 Corporate Governance Report Income Statement 83 Notes to the Financial Statements 84 Group Structure and Shareholders 122 Proposal of the Board of Directors 89 Capital Structure 124 Report of the Statutory Auditor 91 Board of Directors 127 Executive Committee 139 Supplementary Financial Information Compensation, Shareholdings and Loans 143 Investor Information 92 Shareholders’ Participation Rights 143 Statement of Value Added 94 Changes of Control and Defense Measures 144 Free Cash Flow 95 Auditors 145 CORE Results 96 Information Policy and Key Reporting Dates 146 Financial Report
    [Show full text]
  • Supreme Court of the United States
    No. 03-724 IN THE Supreme Court of the United States ———— F. HOFFMANN-LA ROCHE LTD, HOFFMANN-LA ROCHE INC., ROCHE VITAMINS INC., BASF AG, BASF CORP., RHÔNE-POULENC ANIMAL NUTRITION INC., RHÔNE-POULENC INC., et al., Petitioners, v. EMPAGRAN, S.A., et al., Respondents. ———— On Writ of Certiorari to the United States Court of Appeals for the District of Columbia Circuit ———— JOINT APPENDIX ———— ARTHUR F. GOLDEN MICHAEL D. HAUSFELD Counsel of Record Counsel of Record DAVIS POLK & WARDWELL COHEN, MILSTEIN, HAUSFELD 450 Lexington Avenue & TOLL, P.L.L.C. New York, NY 10017 1100 New York Ave., N.W. (212) 450-4000 Washington, D.C. 20005 (202) 408-4600 Attorneys for Petitioner F. Hoffmann-La Roche Ltd Attorneys for Respondents [Names and addresses of additional counsel listed on signature pages of parties’ briefs] PETITION FOR CERTIORARI FILED NOVEMBER 13, 2003 PETITION FOR CERTIORARI GRANTED DECEMBER 15, 2003 TABLE OF CONTENTS Page Chronological List of Relevant Docket Entries............. 1 Notice of Designation of Related Civil Cases Pending In This Or In Any Other United States Court, dated July 17, 2000.............................................................. 3 Plaintiffs’ Amended Class Action Complaint, dated November 14, 2000 ................................................... 6 Order of the United States District Court for the District of Columbia, dated June 7, 2001 .................. 69 ii TABLE OF CONTENTS—Continued Page The following opinions, judgments and orders have been omitted in printing this joint appendix because they appear on the following pages of the appendix to the Petition for Certiorari: Memorandum Opinion of the United States District Court for the District of Columbia, dated June 7, 2001 ..........................................................................
    [Show full text]
  • Annual Report 2016 Corporate Governance Report Segments Financial Report Company Remuneration Report
    Corporate Annual Report 2016 Company Segments Financial Corporate Report Governance Report Remuneration Report Contact us Corporate inquiries and further information, please contact: Global Headquarters Lonza Group Ltd Muenchensteinerstrasse 38 4002 Basel, Switzerland Tel +41 61 316 81 11 Fax +41 61 316 91 11 www.lonza.com Investor Relations Tel +41 61 316 85 40 Fax +41 61 316 95 40 [email protected] Media / Corporate Communications Tel +41 61 316 87 98 Fax +41 61 316 97 98 [email protected] Share Register c/o Computershare Schweiz AG P.O. Box 4601 Olten, Switzerland Tel +41 62 205 7700 Fax +41 62 205 7790 [email protected] Production Details Production Corporate Communications, Lonza Group Ltd, Basel (CH) All rights reserved Design and Illustration Lonza Design Team Website and Programming Lonza Digital Team Photography Gregor Brändli, Basel (CH) with thanks to the Natural History Museum Basel Company Letter to Shareholders Lonza at a Glance Financial Highlights 2016 Governance Management and Company Structure Investor Information Delivering on Our Strategy Sustainable Values Lonza Annual Report 2016 1 Letter to Shareholders Dear Fellow Shareholders, Last year’s record performance was not just a “one­off” result as it represented the fifth year in a row that we delivered improvements on all major financial performance indicators. Since we started our transformational journey in late 2012, we have shown steady and continued improvement in all our key performance indicators, which in turn has been reflected in significant improvements in our share price. We are grateful to you, our shareholders, for the faith you have demonstrated in Lonza with your ownership.
    [Show full text]
  • Schedule of Investments International Equity Portfolio^ (Unaudited) September 30, 2020
    Schedule of Investments International Equity Portfolio^ (Unaudited) September 30, 2020 NUMBER OF NUMBER OF SHARES VALUE SHARES VALUE 108,300 Sanwa Holdings Corp. $ 1,148,343 Common Stocks 96.9% 11,400 SCSK Corp. 637,818 Austria 1.2% (a) 9,400 Shionogi & Co. Ltd. 503,128 25,905 BAWAG Group AG $ 936,585 8,700 TechnoPro Holdings, Inc. 544,720 Belgium 0.7% 17,700 Terumo Corp. 704,720 11,337 KBC Group NV 568,506 15,100 Tokio Marine Holdings, Inc. 660,694 Canada 0.8% 16,100 Toyota Motor Corp. 1,068,557 4,458 Kinaxis, Inc. 656,237* 8,971,615 China 1.2% Luxembourg 0.4% 25,272 Alibaba Group Holding Ltd. 927,763* 7,570 Befesa SA 303,705(a) France 7.3% Netherlands 6.6% 3,942 Air Liquide SA 624,845 4,488 ASML Holding NV 1,657,746 (b) 3,372 Arkema SA 357,514 11,265 Heineken NV 1,002,887 (a) 8,232 Pernod-Ricard SA 1,312,476 28,494 Intertrust NV 485,031 * 8,941 Schneider Electric SE 1,111,356 23,067 Koninklijke Philips NV 1,089,203 5,393 Teleperformance 1,662,672 7,280 NXP Semiconductors NV 908,617 (b) 16,748 TOTAL SE 575,169 5,143,484 5,644,032 Norway 0.7% *(a) Germany 11.4% 73,154 Sbanken ASA 528,710 * 2,683 adidas AG 866,453 Singapore 0.8% 16,232 Brenntag AG 1,032,060 * 44,000 DBS Group Holdings Ltd. 646,859 14,354 CTS Eventim AG & Co.
    [Show full text]
  • LONZA FINANCE INTERNATIONAL NV (Incorporated in Belgium As a Société Anonyme/Naamloze Vennootschap)
    LONZA FINANCE INTERNATIONAL NV (incorporated in Belgium as a société anonyme/naamloze vennootschap) €500,000,000 1.625 per cent. Guaranteed Bonds due 2027 guaranteed by Lonza Group AG (a stock corporation organised under Swiss law) Issue Price: 99.424 per cent. The €500,000,000 1.625 per cent. Guaranteed Bonds due 2027 (the “Bonds”) will be issued by Lonza Finance International NV (the “Issuer”) and guaranteed by Lonza Group AG (the “Guarantor”). Interest on the Bonds will be payable annually in arrear on 21 April in each year, commencing on 21 April 2021. Payments on the Bonds will be made without deduction for or on account of taxes of the Kingdom of Belgium or Switzerland to the extent described under “Terms and Conditions of the Bonds — Taxation”. The Bonds will mature on 21 April 2027 (the “Maturity Date”). The Bonds will be subject to redemption in whole, but not in part at their principal amount, together with accrued interest, at the option of the Issuer (a) during the period between 90 days prior to the Maturity Date (the “Early Call Date”) and the Maturity Date; (b) at any time if 80 per cent. or more in principal amount of the Bonds originally issued have been redeemed (other than where 80 per cent. or more in principal amount of the Bonds originally issued have been redeemed pursuant to the Issuer Make Whole Call Option) or purchased; and (c) at any time in the event of certain changes affecting taxation in the Kingdom of Belgium or Switzerland. The Bonds will also be subject to redemption in whole or in part at the higher of (a) their principal amount or (b) the sum of the then present values of the remaining scheduled payments of principal and interest discounted to the Make Whole Optional Redemption Date (as defined herein) on an annual basis and assuming, for this purpose, that the Bonds are to be redeemed on the date falling 90 days prior to the Maturity Date, in each case together with accrued interest, at the option of the Issuer at any time.
    [Show full text]
  • For a Resilient Future
    For a resilient future 2016 Financial Report Financial highlights Our Group delivered a good net income of USD 3.6 billion, supported by all Business Units. Financial highlights For the years ended 31 December USD millions, unless otherwise stated 2015 2016 Change in % Group Net income attributable to common shareholders 4 597 3 5 5 8 –23 Premiums earned and fee income 30 214 33 231 10 Earnings per share in CHF 12.93 10.55 –18 Common shareholders’ equity 32 415 3 4 5 3 2 7 Return on equity in %1 13.7 10.6 Return on investments in % 3.5 3.4 Net operating margin in %2 17.1 13.0 Number of employees3 12 767 14 0 5 3 10 Property & Casualty Reinsurance Net income attributable to common shareholders4 3 0 08 2 10 0 –30 Premiums earned 15 090 17 0 0 8 13 Combined ratio in %2,4 85.7 93.5 Net operating margin in %2,4 22.5 15.4 Return on equity in %1,4 22.4 16.4 Life & Health Reinsurance Net income attributable to common shareholders4,5 968 807 –17 Premiums earned and fee income5 10 616 11 5 2 7 9 Net operating margin in %2,4,5 12.2 10.4 Return on equity in %1,4,5 16.2 12.8 Corporate Solutions Net income attributable to common shareholders4 357 135 –62 Premiums earned 3 379 3 5 0 3 4 Combined ratio in %4 93.2 101.1 Net operating margin in %4 14.1 4.2 Return on equity in %1,4 15.5 6.0 Life Capital Net income attributable to common shareholders4,5 424 638 50 Premiums earned and fee income5 1 129 1 19 3 6 Gross cash generation6 543 721 33 Net operating margin in %4,5 17.8 27.0 Return on equity in %1,4,5 7.5 10.4 1 Return on equity is calculated by dividing net income attributable to common shareholders by average common shareholders’ equity.
    [Show full text]
  • Full-Year Results 2020 Pierre-Alain Ruffieux, CEO Rodolfo Savitzky, CFO
    Full-Year Results 2020 Pierre-Alain Ruffieux, CEO Rodolfo Savitzky, CFO 27 January 2021 Hong Kong Aerial scene in night, with road and traffic 1 Contents Full-Year 2020 Corporate Overview Full-Year 2020 Financial Summary Lonza Segments: • Pharma Biotech & Nutrition (LPBN) • Specialty Ingredients (LSI) Outlook 2021 and Mid-Term Guidance 2023 Q&A Appendices Urban crowd from above 2 Full-Year 2020 Corporate Overview Aerial view of Independence monument in Mexico City 3 Full-Year 2020 Corporate Overview Strong full-year performance, driven by sales growth in LPBN Lonza delivers on guidance1 with 12.0%2 sales growth, with CHF 4.5 billion sales, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong performance in LPBN with 12.2%2 sales growth and CORE EBITDA margin of 32.1%, driven by Biologics business Production of the drug substance for Moderna COVID-19 Vaccine has commenced at Portsmouth (USA) and Visp (CH) sites LSI3 delivered a solid performance, with 3.4%2 sales growth alongside an improved CORE EBITDA margin, reported at 20.3%4 Winding road at Faroe 1 2020 Guidance relates to Lonza Group results without LSI reported as discontinued operations 2 All sales growth figures are at a constant exchange rate (CER) 3 Specialty Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI) CORE definition: See appendix 4 4 CORE EBITDA margin at
    [Show full text]
  • Fund Risk Management
    FUND RISK MANAGEMENT Monthly Report Umbrella Cosmos Lux International Net Asset Value 10,401,340.66 Sub-fund CHF Currency CHF May 2017 Portfolio date 29/05/2017 FUND ID Fund name Cosmos Lux International TNA end of period 10,401,340.66 NAV end of period 119.34 Sub-fund name CHF TNA start of period 9,945,879.95 NAV start of period 114.11 ISIN LU0989373237 TNA Variation 4.58% NAV Variation 4.58% Currency CHF Benchmark SWISS MARKET INDEX Subscriptions 0.00 FUND RISK PROFILE Low Redemptions 0.00 RISK MANAGEMENT COMMENTS Stale price overview No stale price. Operational risk No material NAV error occurred during the period. No massive redemption occurred during the period. Risk Metrics: Scorecard reporting 4Cs (based on NAV date) Leverage Counterparty risk Concentration risk Liquidity risk . <100% NAV <5% or 10% <10% >90% liquid day Investment Compliance dashboard There are no Breaches to display. Investment Compliance specific NA Total Expense Ratio - Internal limit 3% As of 31/03/2017 (quarterly): Without transaction fees B CAP 2.48% Portfolio Turnover As of 31/03/2017 (quarterly): 12.67% VaR - Leverage NA Liquidity Risk No issue to report. Investment Manager comments 1 FUND RISK MANAGEMENT Monthly Report Umbrella Cosmos Lux International Net Asset Value 10,401,340.66 Sub-fund CHF Currency CHF May 2017 Portfolio date 29/05/2017 Regulatory main limit checks Check result Indicator Check result Indicator Issuer Exposure < 10% NAV 6.32% Cash Counterparty Exposure < 20% NAV 2.59% OECD Govt Bond Exposure < 35% NAV 6.13% OTC Counterparty Exposure NA 5/40 Rule 33.25% Aggregated Group Exposure 6.32% Borrowing limit < 10% NAV NA Cover Rule (liquid assets vs.
    [Show full text]
  • News Release
    News release Swiss Re reports good results, with full-year net income of USD 3.6 billion for 2016; proposes new share buy-back • Group net income of USD 3.6 billion, supported by continued Media Relations, solid underwriting performance and strong investment result Zurich Telephone +41 43 285 7171 • Property & Casualty Reinsurance net income USD 2.1 billion; ROE of 16.4% New York Telephone +1 914 828 6511 • Life & Health Reinsurance net income USD 807 million; ROE of 12.8% Hong Kong Telephone +852 2582 3660 • Corporate Solutions net income USD 135 million; ROE of 6.0% • Life Capital net income USD 638 million; gross cash generation Investor Relations, of USD 721 million and ROE of 10.4% Zurich Telephone +41 43 285 4444 • Continued strong investment performance in challenging yield environment; ROI 3.4% Swiss Re Ltd Mythenquai 50/60 • Capacity reduction due to disciplined underwriting in most P.O. Box segments lead to premium volume decrease in January 2017 CH-8022 Zurich renewals; price quality exceeds hurdle rate • Board of Directors to propose a rise in regular dividend to Telephone +41 43 285 2121 Fax +41 43 285 2999 CHF 4.85 per share and the authorisation of a new public share buy-back programme of up to CHF 1.0 billion www.swissre.com • Swiss Re proposes to elect Jay Ralph and Joerg Reinhardt to the @SwissRe Board of Directors • Matthias Weber to step down as Group Chief Underwriting Officer; Edouard Schmid to succeed him Zurich, 23 February 2017 – Swiss Re delivers a good 2016 performance with full-year net income of USD 3.6 billion, supported by solid underwriting and a strong investment result.
    [Show full text]